[go: up one dir, main page]

AR029627A1 - Derivados de proteina c y composiciones farmaceuticas formuladas con dichos derivados, moleculas de dna recombinante que codifican dichos derivados; vectores de transformacion que comprenden dichos derivados; aislados de acidos nucleicos que comprenden polinucleotidos que codifican al menos el 90% d - Google Patents

Derivados de proteina c y composiciones farmaceuticas formuladas con dichos derivados, moleculas de dna recombinante que codifican dichos derivados; vectores de transformacion que comprenden dichos derivados; aislados de acidos nucleicos que comprenden polinucleotidos que codifican al menos el 90% d

Info

Publication number
AR029627A1
AR029627A1 ARP000101970A ARP000101970A AR029627A1 AR 029627 A1 AR029627 A1 AR 029627A1 AR P000101970 A ARP000101970 A AR P000101970A AR P000101970 A ARP000101970 A AR P000101970A AR 029627 A1 AR029627 A1 AR 029627A1
Authority
AR
Argentina
Prior art keywords
derivatives
protein
polinucleotides
isolated
understanding
Prior art date
Application number
ARP000101970A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR029627A1 publication Critical patent/AR029627A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)

Abstract

Se describen y reivindican nuevos derivados de la proteína C. Se trata de polipéptidos que conservan la actividad biologica de la proteína C humana del tipo silvestre, con semividas en la sangre humana sustancialmente mayor. Estos polipéptidos requerirán una administracion menos frecuente y/o una dosificacion menor que la proteína C humana del tipo silvestre en el tratamiento de trastornos oclusivos vasculares, estados hipercoagulables y enfermedades que predisponen a la trombosis. Específicamente, se trata de derivados de la proteína C humana que comprenden la SEQ ID Ns1. También, se describen y se reivindican los objetos restantes mencionados en el título.
ARP000101970A 1999-04-30 2000-04-26 Derivados de proteina c y composiciones farmaceuticas formuladas con dichos derivados, moleculas de dna recombinante que codifican dichos derivados; vectores de transformacion que comprenden dichos derivados; aislados de acidos nucleicos que comprenden polinucleotidos que codifican al menos el 90% d AR029627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13180199P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
AR029627A1 true AR029627A1 (es) 2003-07-10

Family

ID=22451086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101970A AR029627A1 (es) 1999-04-30 2000-04-26 Derivados de proteina c y composiciones farmaceuticas formuladas con dichos derivados, moleculas de dna recombinante que codifican dichos derivados; vectores de transformacion que comprenden dichos derivados; aislados de acidos nucleicos que comprenden polinucleotidos que codifican al menos el 90% d

Country Status (11)

Country Link
EP (1) EP1090130A1 (es)
JP (1) JP2002542832A (es)
KR (1) KR20010053345A (es)
AR (1) AR029627A1 (es)
AU (1) AU4188500A (es)
BR (1) BR0006088A (es)
CA (1) CA2338799A1 (es)
HU (1) HUP0102444A3 (es)
IL (1) IL140326A0 (es)
PE (1) PE20010066A1 (es)
WO (1) WO2000066754A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351470A1 (en) * 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
WO2001057193A2 (en) * 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
US6630138B2 (en) 2000-02-11 2003-10-07 Eli Lilly And Company Protein C derivatives
JPWO2002028416A1 (ja) * 2000-09-30 2004-02-12 持田製薬株式会社 溶血性貧血の予防・治療剤
AU2002210388B2 (en) * 2000-10-18 2006-11-23 Perseid Therapeutics Llc Protein C or activated protein C like molecules
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2006044294A2 (en) * 2004-10-14 2006-04-27 Eli Lilly And Company Human protein c analogs
JPWO2023171719A1 (es) * 2022-03-08 2023-09-14
KR20250000042A (ko) 2023-06-23 2025-01-02 충남대학교산학협력단 절단 반응성 펩타이드를 발현하는 키메라 t 세포 및 이를 포함하는 감염 질환 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3270462B2 (ja) * 1989-12-29 2002-04-02 ザイモジェネティクス，インコーポレイティド ハイブリッドプロテインｃ
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
AU730133B2 (en) * 1996-11-08 2001-02-22 Oklahoma Medical Research Foundation Modified protein C and methods of use thereof

Also Published As

Publication number Publication date
WO2000066754A1 (en) 2000-11-09
PE20010066A1 (es) 2001-02-02
KR20010053345A (ko) 2001-06-25
EP1090130A1 (en) 2001-04-11
AU4188500A (en) 2000-11-17
BR0006088A (pt) 2001-03-20
IL140326A0 (en) 2002-02-10
HUP0102444A2 (hu) 2001-10-28
CA2338799A1 (en) 2000-11-09
HUP0102444A3 (en) 2003-09-29
JP2002542832A (ja) 2002-12-17

Similar Documents

Publication Publication Date Title
Legler et al. Chemokines: chemistry, biochemistry and biological function
Prockop et al. Collagens: molecular biology, diseases, and potentials for therapy
Ouellette et al. Purification and primary structure of murine cryptdin‐1, a Paneth cell defensin
Kao et al. A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response
KR970707141A (ko) 종양 괴사 인자-감마(Tumor necrosis factor-gamma)
ATE323510T1 (de) Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen
BR9809914A (pt) Genes de moracella receptores de lactoferrina
KR970700438A (ko) 마크로파지 염증성 단백질-3,-4 및 -1감마(MACROPHAGE INFLAMMATORY PROTEINS -3,-4 AND -1sg(g))
ATE360031T1 (de) Chimäre proteine und anwendungen
DK0910647T3 (da) Human DNase i hyperaktive varianter
DK0409472T3 (da) Knoglemorfogenetisk protein
AR029627A1 (es) Derivados de proteina c y composiciones farmaceuticas formuladas con dichos derivados, moleculas de dna recombinante que codifican dichos derivados; vectores de transformacion que comprenden dichos derivados; aislados de acidos nucleicos que comprenden polinucleotidos que codifican al menos el 90% d
JP2515928B2 (ja) 高分子量ヒト血管形成因子
NZ531570A (en) DNA sequences for human angiogenesis genes
ES2124470T3 (es) Lectina recombinante de muerdago.
PT1439231E (pt) ''rantes truncada na extremidade amino como antagonistaas de quimiocinas''
BR9911349A (pt) Genes para a biossìntese de epotilonas
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
AR020329A1 (es) UNA SUSTANCIA, EN PARTICULAR UNA RIBOZIMA, CAPAZ DE INHIBIR LA EXPRESION DE PRESENILINA 2, UNA MOLECULA DE DNA RECOMBINANTE QUE CODIFICA DICHA RIBOZIMA, UNVECTOR RECOMBINANTE QUE COMPRENDE EL cDNA CORRESPONDIENTE A DICHA RIBOZIMA, UNA CELULA HOSPEDADORA QUE COMPRENDE DICHO VECTOR RECOMBINANTE, UNA C
DE50010519D1 (de) Pharmazeutische Zusammensetzungen zur Therapie der Herzinsuffizienz
HU205617B (en) Process for producing neturophyl-activating factor, gene coding this and pharmaceutical composition
ATE362547T1 (de) Polymorphismen im menschlichen kdr gene
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
US6121237A (en) Neutrophil stimulating peptides